GP0702D mHSPC & mCRPC patients in the US

Global Patients is collaborating on a research study with IQVIA™, a worldwide healthcare consulting firm, and a pharmaceutical company. The aim is to explore the symptoms of prostate cancer and how they have impacted the quality of life of patients and get feedback on a questionnaire designed to assess symptoms.

We are seeking patients who have been diagnosed with either metastatic hormone sensitive (mHSPC) or metastatic castration resistant prostate cancer (mCRPC).

Study participation involves a web assisted interview of 90 minutes with a healthcare professional. As a token of appreciation for their time and insight participants receive a $125 e-gift card.

If you or someone you know is interested do not hesitate to contact :

Join this Study
Are you already a member of Global Patients?